Jafron Biomedical Co (SZSE:300529) Long-Term Capital Lease Obligation : ¥9 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Long-Term Capital Lease Obligation?

Jafron Biomedical Co's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥9 Mil.

Jafron Biomedical Co's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (¥12 Mil) to Dec. 2023 (¥11 Mil) and declined from Dec. 2023 (¥11 Mil) to Mar. 2024 (¥9 Mil).

Jafron Biomedical Co's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (¥17 Mil) to Dec. 2022 (¥17 Mil) but then declined from Dec. 2022 (¥17 Mil) to Dec. 2023 (¥11 Mil).

Jafron Biomedical Co Long-Term Capital Lease Obligation Historical Data

The historical data trend for Jafron Biomedical Co's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Long-Term Capital Lease Obligation Chart

Jafron Biomedical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

11.77

17.01

17.34

11.35

Jafron Biomedical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															15.96	13.31	12.18	11.35	9.07

Jafron Biomedical Co (SZSE:300529) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Jafron Biomedical Co Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Jafron Biomedical Co (SZSE:300529) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085

Website

http://www.jafron.com

Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.

Executives

Li Feng	Director
He Xiao Lian	Executives
Dong Fan	Directors, Directors, and Executives
Ceng Kai	Directors, executives
Tang Xian Min	Directors, executives
Zhang Ming Yuan	Secretary Dong
Fang Li Hua	Supervisors
Zhang Guang Hai	Directors, executives
Li De Zhi	Executives
Lu Shao Zhang	Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines